Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
E Shutov, W Sułowicz, C Esposito… - … : Official Publication of …, 2021 - europepmc.org
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - search.ebscohost.com
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
[引用][C] Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A Phase 3, randomized, double-blind, placebo-controlled study (ALPS …
E Shutov, W Sułowicz, C Esposito, A Tataradze… - Nephrology Dialysis …, 2021 - elibrary.ru
[PDF][PDF] Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS …
E Shutov, W Sułowicz, C Esposito… - Nephrol Dial …, 2021 - scholar.archive.org
Background. Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods. This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods. This Phase 3 …
[HTML][HTML] Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study …
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - ncbi.nlm.nih.gov
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
[PDF][PDF] Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS …
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3 …
[PDF][PDF] Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS …
E Shutov, W Sułowicz, C Esposito… - Nephrol Dial …, 2021 - pdfs.semanticscholar.org
Background. Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods. This Phase 3 …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods. This Phase 3 …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
E Shutov, W Sułowicz, C Esposito… - Nephrology Dialysis …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the …
Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the …
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
E Shutov, W Sulowicz, C Esposito… - NEPHROLOGY …, 2021 - iris.unipv.it
BACKGROUND: Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase
inhibitor for the treatment of chronic kidney disease (CKD) anemia. METHODS: This Phase …
inhibitor for the treatment of chronic kidney disease (CKD) anemia. METHODS: This Phase …